- Home
- RNAZ vs ALBT Comparison
RNAZ vs ALBT Comparison
Compare RNAZ & ALBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNAZ
- ALBT
- Stock Information
- Founded
- RNAZ 2016
- ALBT 2014
- Country
- RNAZ United States
- ALBT United States
- Employees
- RNAZ N/A
- ALBT N/A
- Industry
- RNAZ Biotechnology: Pharmaceutical Preparations
- ALBT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RNAZ Health Care
- ALBT Health Care
- Exchange
- RNAZ Nasdaq
- ALBT Nasdaq
- Market Cap
- RNAZ 6.1M
- ALBT 5.7M
- IPO Year
- RNAZ 2021
- ALBT N/A
- Fundamental
- Price
- RNAZ $9.11
- ALBT $2.71
- Analyst Decision
- RNAZ Strong Buy
- ALBT
- Analyst Count
- RNAZ 1
- ALBT 0
- Target Price
- RNAZ $280.00
- ALBT N/A
- AVG Volume (30 Days)
- RNAZ 26.1K
- ALBT 645.0K
- Earning Date
- RNAZ 08-13-2025
- ALBT 08-18-2025
- Dividend Yield
- RNAZ N/A
- ALBT N/A
- EPS Growth
- RNAZ N/A
- ALBT N/A
- EPS
- RNAZ N/A
- ALBT N/A
- Revenue
- RNAZ N/A
- ALBT $807,235.00
- Revenue This Year
- RNAZ N/A
- ALBT N/A
- Revenue Next Year
- RNAZ N/A
- ALBT N/A
- P/E Ratio
- RNAZ N/A
- ALBT N/A
- Revenue Growth
- RNAZ N/A
- ALBT N/A
- 52 Week Low
- RNAZ $6.15
- ALBT $2.11
- 52 Week High
- RNAZ $905.52
- ALBT $12.60
- Technical
- Relative Strength Index (RSI)
- RNAZ 55.86
- ALBT 42.27
- Support Level
- RNAZ $8.04
- ALBT $2.54
- Resistance Level
- RNAZ $9.70
- ALBT $2.74
- Average True Range (ATR)
- RNAZ 0.67
- ALBT 0.31
- MACD
- RNAZ 0.27
- ALBT 0.00
- Stochastic Oscillator
- RNAZ 75.08
- ALBT 13.97
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.
About ALBT Avalon GloboCare Corp.
Avalon Globocare Corp is an intelligent biotech developer and healthcare service provider dedicated to promoting and empowering high-impact, transformative biotechnology, clinical applications, and healthcare facility management. The company has two reportable segments: the real property operating segment, which is the key revenue driver, and the laboratory testing services segment. The company focuses on diagnostic and therapeutic areas like early detection of oral cancer, ovarian cancer, kidney cancer, skin regeneration and anti-fibrosis, and treatments of degenerative disorders.